By Olivia Bugault

Fresenius Kabi India has reached an agreement with the U.S. Department of Justice to conclude an investigation that started in 2013.

"Under the agreement, which still must be reviewed and accepted by the U.S. District Court for the District of Nevada, Fresenius Kabi Oncology Ltd. will make a payment of $50 million," said the unit of German healthcare company Fresenius SE & Co. The company said late Tuesday that the agreement wouldn't affect its income.

Fresenius Kabi India terminated the contracts of several of its employees at a plant in Kalyani, India, in 2013 after it discovered they didn't provide 'relevant records' during an investigation from the U.S. Food & Drug Administration, the company said.

Write to Olivia Bugault at olivia.bugault@wsj.com

(END) Dow Jones Newswires

02-10-21 0128ET